Financial Daily from THE HINDU group of publications
Wednesday, Aug 04, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - New Projects


Dr Lal PathLabs scouts for partner to fund expansion

P.T. Jyothi Datta

Mumbai , Aug 3

THE New Delhi-based Dr Lal PathLabs Pvt Ltd is looking to get on board a private investor to support its countrywide expansion plans.

This comes even as the over 50-year-old diagnostic labs chain sets about establishing what is touted to be among Asia's biggest pathlabs, on the outer fringes of New Delhi.

"We are scouting for a partner and the exercise should be wrapped up shortly," said Dr Arvind Lal, Managing Director of the company. Ernst and Young have been consultants to the diagnostics company for the last five years.

The Rs 40-crore pathlab chain expects to double the number of collection centres that it has across the country, to touch 500 in five years, in addition to establishing about 50 labs. At present, the network comprises 10 labs and 250 collection centres.

Elaborating on the mega laboratory project to be established at Rohini, on the outskirts of Delhi, he said that the Rs 22-crore project would come up by 2006. Finance for the project is being raised from banks, he said.

The pathlab chain caters to almost 3,000 patients per day and offers over 1,500 different investigations and tests. Dr Lal was in the city recently for the launch of neonatal screening or screening of infants using Tandem Mass Spectrometry. Touted to be a first of sorts in South Asia, he said that the advanced tests screen children for genetic disorders called Inborn Errors of Metabolism (IEM).

The IEM testing profile will enable the diagnosis of 60 different metabolic disorders, 40 of these will be tested using a blood specimen collected on an IEM screening card or a special filter paper, he said. The test is done on neonates in the age group of 0-28 days, but it can be done on children and adults too.

IEM are basically genetic defects in enzymes/proteins used to metabolise proteins, fats and carbohydrates that result in deficiency or toxic accumulation of these metabolites in the system. If untreated, these can cause irreversible damage, leading to serious mental retardation, autism, learning disabilities and even death, he pointed out. The test assumes significance since about four crore people in the country suffer from mental retardation.

More Stories on : New Projects | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
P&G, CSIR tie up to create breakthrough innovations


Glenmark's Ankleshwar unit gets FDA nod
Ocimum licenses gene tool to 2 Canadian cos
Philips arm gets projector deal
Torrent launches painkiller
Gujarat Oleo Chem bags Rs 25-cr biodiesel order from IOC
Colour Chem open offer case comes up in SC
M&A scene in India — a tepid H1 2004
Nod for fresh share transfers — Gillette explains stake buys to Govt
Asahi India plans expansion, to invest Rs 600 cr
Dr Lal PathLabs scouts for partner to fund expansion
Optimism on Volkswagen setting up unit in Vizag
NIS Sparta plans China foray
Siemens in pact with Italy's Aethra — To offer conferencing solutions
Yash Birla Group to launch educational books
Technical panel to study IDPL revival
Non-compliance of order — BIFR issues notice in Cimmco Birla case
Sun Pharma eyes tie-ups in Europe
Man Industries expects 15 pc topline growth
Toyota Kirloskar Auto may notch Rs 400-cr sales in first year
Asian Paints aims to boost global biz
Samtel to focus on premium TV
Corporates sustain Q1 growth momentum



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line